Giving generic drugmakers a two-year reprieve and setting the path for steep duties thereafter, US President Donald Trump on Tuesday announced a phased tariff plan for imported generic medicine.
Trump's new plan offers manufacturers a two-year window before imposing sharply higher import duties as part of a broader push to relocate pharmaceutical production to the US.